Legal access to marijuana, medicinal or otherwise, is growing. In 2016, four states approved recreational use of the drug and four states passed laws related to medical-cannabis access, bringing the total number of states that allow some form of legal marijuana use to 28.
Scientists know that marijuana contains more than 100 compounds, called cannabinoids, that have biological effects on the body. Mdically, cannabis can be prescribed for physical ailments like arthritis and cancer symptoms as well as mental health issues like PTSD, depression and anxiety. Still, the role marijuana can play in medicine remains murky. The dearth of research is in large part due to the fact that most studies have focused on illicit use of marijuana rather than its therapeutic potential, and because it’s classified as a schedule 1 drug, making it nearly impossible to study.
Though more research is needed, studies also suggested that cannabis may have a place in dealing with addiction. “We are really excited about the potential substitution effect,” says study author Zach Walsh, an associate professor of psychology at the University of British Columbia. “If people use cannabis as a replacement for opioid medications, or to get off of opioids or cut back, we could see some pretty dramatic public health benefits. The level of opioid overdoses is so high right now.”
There’s evidence to support that potential. Another unrelated study suggested that pot may even have a place in curbing the opioid epidemic. And yet marijuana can be notoriously hard to study in the U.S. because it’s classified as a Schedule 1 drug, which means it has a high potential for abuse. Many scientists and medical professionals think the classification hampers research, and that marijuana’s medical potential merits further exploration. More studies, research advocates argue, would also help eliminate stigma associated with the drug, paving the way for more and better studies.
“I think people will derive more benefit if they can speak more openly with providers about whether they are using cannabis and why,” says Walsh.
Walsh is a lead investigator on a clinical trial of cannabis that is being funded by a medical cannabis producer called Tilray. Another researcher on the study has been a consultant for other medical cannabis producers. When asked if this represents a conflict of interest, Walsh points out that funding for marijuana-related research is hard to come by. ” I think we are entering a different world,” he says, “but for now a lot of the research, at least in Canada, is funded by the producers.”